Search

Search Constraints

You searched for: Author/Creator Abraham, Renny

Search Results

2. 0120 SUVN-G3031, a Novel, Potent and Selective Histamine H3 Receptor Inverse Agonist for the Treatment of Narcolepsy: Preclinical Characterization. (12th April 2019)

3. 0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates. (12th April 2019)

4. 0265 Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Narcolepsy. (25th May 2022)

5. [P1–063]: SUVN‐G3031, A SELECTIVE H3 RECEPTOR INVERSE AGONIST: ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS. (1st July 2017)

6. [P1–079]: SUVN‐I6107: A NOVEL MUSCARINIC M1 RECEPTOR‐POSITIVE ALLOSTERIC MODULATOR (M1‐PAM) DEVOID OF CHOLINERGIC SIDE EFFECTS. (1st July 2017)

7. [P1–098]: SUVN‐502 (5‐HT6 ANTAGONIST) POTENTIATES THE EFFECTS OF MEMANTINE IN ANIMAL MODELS OF COGNITION. (1st July 2017)

8. [P1–460]: SUVN‐D4010: A POTENT AND SELECTIVE 5‐HT4 RECEPTOR PARTIAL AGONIST— ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS. (1st July 2017)

9. [P2–033]: SUVN‐502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER's DISEASE. (1st July 2017)